Entera Bio (NASDAQ:ENTX) Issues Earnings Results, Misses Estimates By $0.06 EPS

Entera Bio (NASDAQ:ENTX) released its quarterly earnings data on Friday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06), Zacks reports.

Entera Bio Stock Up 1.8%

ENTX stock traded up $0.05 during trading on Friday, hitting $2.87. The company had a trading volume of 244,911 shares, compared to its average volume of 4,887,891. The firm has a 50-day moving average price of $1.85 and a 200-day moving average price of $1.49. The firm has a market cap of $141.46 million, a PE ratio of -10.63 and a beta of 1.38. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Entera Bio currently has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Superstring Capital Management LP purchased a new position in shares of Entera Bio in the 4th quarter valued at approximately $33,000. Citadel Advisors LLC lifted its holdings in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the period. HighTower Advisors LLC boosted its stake in shares of Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares in the last quarter. Jane Street Group LLC grew its holdings in Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after acquiring an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after acquiring an additional 19,601 shares during the period. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.